Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 5/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12308335 | 0.80 | CHRNB2 (0.53) | HSD11B1DPP4 | |
| SCHEMBL1463515 | 0.80 | CHRNB2 (0.58) | EPHX2 | |
| SCHEMBL14748127 | 0.79 | EPHX2 (0.43) | EPHX2DPP4DPP8DPP9DPP7 | |
| SCHEMBL22624456 | 0.79 | EPHX2 (0.45) | EPHX2DPP4DPP8DPP9DPP7 | |
| SCHEMBL20343392 | 0.78 | HSD11B1 (0.40) | EPHX2HSD11B1DPP4DPP8DPP9 | |
| SCHEMBL20343596 | 0.78 | HSD11B1 (0.40) | EPHX2HSD11B1DPP4DPP8DPP9 | |
| SCHEMBL20343589 | 0.78 | HSD11B1 (0.40) | EPHX2HSD11B1DPP4DPP8DPP9 | |
| SCHEMBL18348011 | 0.76 | CHRNB2 (0.53) | HSD11B1DPP4DPP7 | |
| SCHEMBL13828093 | 0.76 | EPHX2 (0.44) | EPHX2DPP4DPP8DPP9DPP7 | |
| SCHEMBL20343439 | 0.75 | HSD11B1 (0.44) | HSD11B1DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | VNN1, DPYD, MVD | EPHX2 1659/4885HSD11B1 4206/4885DPP4 89/4885 |
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | VNN1, DPYD, MVD | EPHX2 1772/4885HSD11B1 4296/4885DPP4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.